- Conditions
- Macular Degeneration
- Interventions
- ranibizumab, verteporfin
- Drug
- Lead sponsor
- Texas Retina Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 263
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Macular Edema, Hard Lipid Exudates
- Interventions
- ranibizumab 0.3mg
- Drug
- Lead sponsor
- South Coast Retina Center; Carson, McBeath, Boswell, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more
- Conditions
- Macular Edema, Diabetic
- Interventions
- Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
- Conditions
- Fibrovascular Pigment Epithelial Detachment
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- LMG324, Ranibizumab 0.5 mg, Sham
- Biological
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- ranibizumab intravitreal injection
- Drug
- Lead sponsor
- Hawaii Pacific Health
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Honolulu, Hawaii • ‘Aiea, Hawaii
- Conditions
- Glaucoma, Open-Angle, Failing Bleb Following Trabeculectomy
- Interventions
- Ranibizumab (Lucentis)
- Drug
- Lead sponsor
- The New York Eye & Ear Infirmary
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 6 participants
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age Related Macular Degeneration (AMD)
- Interventions
- Health Management Tool (HMT)
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 23
- States / cities
- Beverly Hills, California • Sacramento, California • Torrance, California + 20 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- LUBT010 (proposed ranibizumab biosimilar), Lucentis (ranibizumab)
- Drug
- Lead sponsor
- Lupin Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Delray Beach, Florida • Hagerstown, Maryland + 3 more
- Conditions
- Macular Degeneration
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Steven R. Sanislo
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- San Francisco, California • Stanford, California
- Conditions
- Choroidal Neovascularization
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Vision Research Foundation
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Diabetic Macular Edema
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 5
- States / cities
- Bakersfield, California • Oxnard, California • Santa Barbara, California + 2 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- reduced fluence photodynamic therapy with Visudyne, Lucentis
- Drug
- Lead sponsor
- Barnes Retina Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
- Interventions
- PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
- Device · Drug
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Age-related Macular Degeneration
- Interventions
- E10030
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Macular Degeneration
- Interventions
- bevasiranib, ranibizumab
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more
- Conditions
- Choroidal Neovascularization
- Interventions
- Faricimab, Ranibizumab, Sham Procedure
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
- Conditions
- Choroidal Neovascularization
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab, Aflibercept
- Drug
- Lead sponsor
- Associated Retinal Consultants, Michigan
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
- Interventions
- 700 ug dexamethasone, ranibizumab, sham
- Drug · Biological · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Fort Myers, Florida • Abilene, Texas
- Conditions
- Diabetic Macular Edema
- Interventions
- Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
- Drug
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab, Ranibizumab plus Photodynamic therapy
- Drug
- Lead sponsor
- Illinois Retina Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Oak Park, Illinois
- Conditions
- Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- AKB-9778, ranibizumab, Placebo, Sham
- Drug
- Lead sponsor
- Aerpio Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 39
- States / cities
- Pheonix, Arizona • Tucson, Arizona • Arcadia, California + 35 more